Jul22493 23. Venous blood sampling remains the standard for biobanking and clinical analysis, but there is a growing interest in simplifying sample collection. As molecular analysis costs decrease, repeated sampling of proteins and transcripts – both responsive to physiological and pathological changes – becomes increasingly valuable. Traditional blood draws require trained personnel, specialised equipment, and can cause unnecessary stress for patients and study participants. SampleFacts is redefining sample collection with its next-generation capillary blood sampling technology, enabling dried cell and plasma collection that is fast, convenient, cost-effective, and reliable. We spoke with Maryan Poorafshar, CEO of SampleFacts, to learn more. SampleFacts was founded in 2023, building on the groundbreaking work conducted by Professor Ulf Landegren and Dr. Johan Björkesten at Uppsala University. Based on decades of combined expertise, their research has inspired the creation of an intuitive microsampling device that break down barriers often associated with traditional blood sample collection. Now, SampleFacts’ mission is clear: to transform sample collection with instant separation technology, empowering research and healthcare with accuracy, efficiency, and limitless applications. Dried blood spot sampling is a non-invasive method of collecting blood, requiring only a small drop of blood from a finger prick placed on a special filter paper. Widely used in pharmacokinetics, newborn screening, and other medical studies, this method offers multiple advantages over traditional venous collection, including greater convenience, accessibility, minimal invasiveness, improved stability, and reduced costs and waste. While its transportability and storage without refrigeration make it highly practical, lab analyses typically require separation of blood cells and plasma, rather than whole blood, a step performed through centrifugation. “We offer a solution that enables instant separation of blood cells and plasma from a single drop of blood,” Maryam told us. “With these characteristics, the sample collection cards we develop provide a reliable and efficient method to collect and store blood samples, addressing the growing demand for remote sampling for biobanking and for analysis. The technology improves the efficiency of clinical trials and laboratory analysis of both multi-omic and more standard biomarkers in blood cells and plasma.” Of all the capillary blood sampling devices on the market, none shine quite so bright as that of SampleFacts. Compared to other dried blood spot devices, SampleFacts’ technology offers the advantage of instant separation of blood cells and plasma, also lowering the influence of variable haematocrit in the process. Additionally, the device is designed for convenient handling by sample donors, minimizing variability, while also being easy to store and process using punching robots, available in many laboratories. The ability to collect small sample punches for analysis, while preserving the rest for further analysis, makes it an excellent fit for longitudinal studies and biobanking. These elements also make SampleFacts’ device an ideal tool for remote sampling, which has been proven by peer-reviewed studies to significantly improve clinical trial recruitment, compliance and retention, as well as cost-efficiency. By addressing logistical barriers and making the process more convenient, remote sampling helps to engage a broader pool of participants and encourages them to remain committed to the study, leading to successful trials. The improved sample collection and handling will also benefit healthcare and wellness broadly, as remote blood sampling makes blood analyses more accessible for individuals in remote, rural, or underserved areas, where access to clinics and phlebotomists can be limited. Easier access to a home blood sampling device will make it simpler for healthcare providers to monitor the treatment and the disease course of their patients on a regular basis and at acute phases, allowing for early detection and adjusted therapy. The goal for SampleFacts is to serve biobanking, drug development and research, while in the longer run its proprietary dried blood spot device can also become an integral part of remote care, facilitating the monitoring of chronic diseases, as well as risk analysis prior to diagnosis. As remote care expands, many governments now reimburse virtual visits, and countries such as the U.S., Germany, and parts of Asia support digital health solutions. Healthcare is shifting from episodic care to continuous monitoring, with a strong focus on chronic diseases, mental health, and preventive screening. Moving forward, SampleFacts aims to secure CE certification, paving the way for broader adoption. The company is establishing an automated manufacturing line for streamlined, large-scale production. A key focus will be to secure commercial agreements that can provide recurring revenue, ensuring longterm sustainability. Additionally, plans for geographic expansion will be set in motion, bringing SampleFacts’ innovative dried blood spot technology to new markets. With these milestones in place, SampleFacts is poised to make a lasting impact on the future of remote care, bringing innovative solutions to patients and healthcare providers around the world. Contact: Maryam Poorafshar Company: SampleFacts Web Address: www.samplefacts.com Most Innovative Blood Sampling Company 2025 – Sweden
RkJQdWJsaXNoZXIy NTY1MjM3